Reminder Emails to Improve Pneumococcal Vaccine Completion at 12 Months of Age

Ottawa Hospital Research Institute700 enrolled

Overview

The goal of this clinical trial is to assess the effectiveness of enhanced email reminders in improving vaccine coverage at the 12-month visit in CANImmunize app users. The main questions it aims to answer are: * Do enhanced email reminders improve coverage of the 12- month dose of the pneumococcal vaccine and the timely completion of its immunization series at the 12-month's visit in CANImmunize app users? * What are the predictors of predictors of timely completion of the 12-month's series of pneumococcal vaccines in the CANImmunize app users? Participants will be randomized to either receive enhanced reminder/recall materials via email or the standard CANImmunize notifications. Researchers will compare the enhanced reminder group to the standard notification group to see if there is a difference in vaccine coverage at the 12-month visit.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

NONE

Enrollment

700

Conditions

Pneumococcal Vaccines Immunization Coverage

Interventions

The intervention is sending enhanced (modality and frequency) of reminders to CANImmunize App users, in addition to the standard notifications. Specifically: * Deliver reminders and recall emails to parents or guardians of infants waiting for their 12-month dose of pneumococcal vaccine, * Add additional information about the benefits, safety and effectiveness of the pneumococcal vaccine to support increased uptake, and * Provide tips to improve parents' or guardians' self-efficacy in circumventing barriers to timely immunization of children at the 12-month's visit

Eligibility

Sex: ALLMin age: 10 MonthsMax age: 11 MonthsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria To be included in the study, CANImmunize account holders must have: * Enabled the reception to receive emails from CANImmunize, and * Record(s) for an infant aged between 10- and 11-months, who have already received the earlier doses of the pneumococcal vaccine in accordance with their provincial/territorial routine immunization schedule. Exclusion Criteria * The account holder (parent, or guardian of the child) has an inactive or undelivered email address, or * No record(s) for an infant aged 10- and 11-months, or * The record for the 10- or 11-month-old indicates that he/she has not received the prior pneumococcal vaccine doses.

Outcomes

Primary Outcomes

Receipt of 12-month pneumococcal vaccine

Receipt of the 12-month dose of the pneumococcal vaccine as recorded in the CANImmunize immunization record

Time frame: 12 months of age

Secondary Outcomes

Timeliness of 12-month pneumococcal vaccine

Age at receipt of the 12-month dose of the pneumococcal vaccine as recorded in the CANImmunize immunization record

Time frame: 12-13 months of age will be considered as timely, after 13 months considered late